CLIENTES - ACCESO PRIVADO    Suscribirse a nuestras novedades (RSS)        
 
BÚSQUEDA:        Buscar
Libros nacionales y extranjeros para bibliotecas,
 
 
Búsqueda avanzada
Libros nacionales y extranjeros para bibliotecas, escuelas, universidades, librerías
     
         
  Arte
Astronomía
Botánica
Ciencia y conocimiento
Ciencias aplicadas / tecnología
Ciencias biológicas
Ciencias sociales
Economía
Filosofía
Física
Generalidades
Geografía
Geología
Historia
Infantil / juvenil
Informática
Ingeniería
Lingüística / filología
Literatura
Matemáticas
Material complementario
Medicina
Ocio
Paleontología / fósiles
Química
Religión y teología
Zoología
   
   
 
   
Los Andes Libros s.l. + 34 935 00 39 13
C/ Andalusia, 3 Local 5 - 08014 Barcelona
 
Handbook of Therapeutic Antibodies
Dübel, Stefan
Handbook of Therapeutic Antibodies
ean9783527314539
temáticaFARMACIA
año Publicación2007
idiomaINGLÉS
editorialWILEY
páginas1228
formatoCARTONÉ


499,00 €


   PEDIR
 
NOVEDAD
 
Últimas novedades
farmacia

In this most comprehensive reference source for the development, production and therapeutic application of antibodies, Volume I contains general chapters presenting established technologies and clinical applications. Volume II provides a look at emerging technologies, new therapeutic concepts, and clinical studies. The third volume features detailed and specific information about each currently approved type of antibody, including the clinical data.
A must-have resource for academic researchers, decision makers in industry and healthcare professionals in the clinic.
indíce

Volume I: Technologies
Foreword
A Greeting from the Editor
PART 0: INTRODUCTION
Therapeutic Antibodies - From Past to Future
PART I: SELECTING AND SHAPING THE ANTIBODY MOLECULE
Selection strategies I: Monoclonal Antibodies
Selection strategies II: Antibody Phage Display
Selection strategies III: Transgenic Mice
Bioinformatic Tools for Antibody Engineering
Molecular Engineering I: Humanization
Molecular Engineering II: Affinity Maturation
Molecular Engineering III: Fc Engineering
PART II: THE WAY INTO THE CLINIC
Production and Downstream Processing
Pharmaceutical Formulation and Clinical Application
Immunogenicity of Antibody Therapeutics
Regulatory Considerations
Intellectual Property Issues

Volume II: Emerging Developments
PART III: BEYOND IGG: MODIFIED ANTIBODIES
Immunoscintigraphy and Radioimmunotherapy
Bispecific Antibodies
Immunotoxins /
Targeted RNases
PART IV: EMERGING CONCEPTS
Automation of Selection and Engineering
Emerging Technologies for Antibody Selection
Emerging Alternative Production Systems
Non-Antibody Scaffolds
Emerging Therapeutic Concepts I: ADEPT
Emerging Therapeutic Concepts II: Nanotechnology
Emerging Therapeutic Concepts III:Cell-bound antibodies
Emerging Therapeutic Concepts IV:Anti-idiotypic Antibodies
PART V: ONGOING CLINICAL STUDIES:
Antibodies in Phase I/II/III: Cancer Therapy
Antibodies in Phase I/II/III: Targeting TNF

VOLUME III: APPROVED THERAPEUTICS
Adalimumab (Humira)
Alemtuzumab (Mabcampath)
Bevacizumab (Avastin)
Cetuximab (Erbitux)
Efalizumab (Raptiva)
Fanolesomab/Technetium99m (Neutrospec)
Gemtuzumab Ozogamicin (Mylotarg)
Infliximab (Remicade)
Muromonab (Orthoclone)
Natalizumab (Tysabri)
Omalizumab (Xolair)
Palivizumab (Synagis)
Rituximab (Rituxan)
Trastuzumab (Herceptin)
Overview: Abciximab, Arcitumomab, Basiliximab, Capromab, Cotara, Daclizumab, Edrecolomab, Ibritumomab, Igovomab, Nofetumomab, Satumomab, Sulesomab, Tositumomab and Votumumab

Finançat per UE